Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)

NCT02228369 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02228369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02228369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
November 5, 2014
Completion date
October 28, 2020
Enrollment
108 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

egfr mutation positive advanced non small cell lung cancer